SCHEMBL6506320

SCHEMBL6506320

O=C1N=C(Nc2ccccc2F)SC1CC(=O)N1CCCc2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ATM Q13315 1/20 0.42
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
MAPK1 P28482 2/20 0.41
GRM7 Q14831 1/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508360 0.89 ALDH1A1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL6428309 0.87 GRM7 (0.46) ALDH1A1SMN1; SMN2MAPTTSHRMAPK1
SCHEMBL6388619 0.86 LMNA (0.47) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL6427597 0.83 ALDH1A1 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL6505625 0.82 MEN1 (0.43) L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6427674 0.82 MAPT (0.44) MEN1KMT2AALDH1A1MAPTTSHR
SCHEMBL6506436 0.81 TSHR (0.53) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL6502545 0.81 TSHR (0.53) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL6500660 0.81 TSHR (0.53) MEN1KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL6428381 0.80 ALDH1A1 (0.46) L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 L3MBTL1 4470/4885MEN1 979/4885KMT2A 3213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.